Anti-obesity Drugs are pharmacological agents that reduce or control the weight. These drugs change one of the fundamental processes of human body, weight regulation, either by changing the absorption of calories or dipping the hunger. Appetite control is achieved by using the agonists for appetite suppressing pathways. Various anti-obesity drugs, which are approved from the past decade such as knoll and acomplia (romonabant) are removed, as they cause suicidal thoughts, depression, and cardiovascular problems, due to their long-term usage.
Ask Free Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/2824
Global Anti-Obesity Drugs Market- Dynamics
Increasing prevalence of obesity, adoption of deskbound lifestyle, increasing geriatric population, and chronic nature of disease is expected to augment market growth. Furthermore, faulty eating habits and rising consumption of fast food coupled with lack exercise is driving the market globally. In October 2018, Novo Nordisk launched new obesity treatment on world obesity day. The company announced the availability of Saxenda in Singapore, which is a Health Sciences Authority (HSA) approved injectable medicine that is used with low calorie meal plan and helps the adults who are obese or who are overweight with at least one weight associated medical problem to lose weight.
Basic activities such reducing the intake of unhealthy food and inculcating workout are not seen to be highly effective, and the medical devices such as intragastric balloon and bariatric surgery have complications and are highly expensive. All this shows difficulties in treatment of obesity. These unmet needs are driving growth of global anti-obesity drugs market. For instance, in September, 2014, the U.S. FDA’s approved a new prescription weight loss pill- Contrave for obese adults, the new drug is the third prescription weight loss drug approved by the FDA.
Global Anti-Obesity Drugs Market- Regional Dynamics
North America has witnessed significant growth in the recent past, owing to high level of awareness among the people with obesity and the higher risks associated with the medical condition, rise in healthcare expenditure, extensive and effective research and development activities, involvement of government and non-government organizations in creating an awareness and funding the research and higher number of adults with obesity in the region. According to the World Health Organization, in 2016, over 1.9 billion adults who were aged 18 years and above were overweight and of these over 650 million were obese.
Global Anti-Obesity Drugs Market- Competitive Analysis
Manufactures are focused on development, manufacturing, and marketing of multisource and branded pharmaceuticals. Key players in the global anti-obesity drug market are innovating new and efficient anti-obesity drugs by adopting novel strategies to meet the demand from customers with various types of obesity problems. For instance, in 2017, Boehringer Ingelheim GmbH and Gubra announced collaboration and license agreement for the development of novel peptide compounds to treat the obesity. Furthermore, in March, 2019, Merck and Co and NGM Biopharmaceuticals developed new range of obesity management drugs.
Grab Your Report @ https://www.coherentmarketinsights.com/insight/buy-now/2824
Key players operating in the global anti-obesity drugs market include Arena Pharmaceuticals Inc., Boehringer Ingelheim GmbH, Eisai Co. Ltd., Orexigen Therapeutics Inc., Norgine B.V., Pfizer Inc., Merck Co& Inc., Takeda Pharmaceuticals Co. Ltd., Zydus Cadila, Novo Nordisk, Zafgen, GlaxoSmithKline PLC, and Hoffmann-La Roche AG
This post was originally published on The Market Plan